NYSE:NGVTIngevity Stock Price, Forecast & News

Ingevity's stock was trading at $38.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NGVT stock has increased by 43.2% and is now trading at $55.56. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ingevity.

Ingevity is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Ingevity.

Ingevity will be holding an earnings conference call on Wednesday, July 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Ingevity Corp (NYSE:NGVT) released its quarterly earnings data on Wednesday, April, 29th. The company reported $1.12 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.84 by $0.28. The business earned $288.20 million during the quarter, compared to the consensus estimate of $263.61 million. Ingevity had a return on equity of 45.48% and a net margin of 15.82%. The firm's revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.99 earnings per share. View Ingevity's earnings history.

Ingevity updated its second quarter 2020 After-Hours earnings guidance on Wednesday, April, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $246.96-264.6 million, compared to the consensus revenue estimate of $325.64 million.

7 Wall Street analysts have issued 1 year target prices for Ingevity's stock. Their forecasts range from $42.00 to $107.00. On average, they expect Ingevity's share price to reach $73.14 in the next year. This suggests a possible upside of 31.6% from the stock's current price. View analysts' price targets for Ingevity.

News stories about NGVT stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ingevity earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news about Ingevity.

Ingevity saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 1,400,000 shares, a drop of 11.4% from the June 15th total of 1,580,000 shares. Based on an average daily trading volume, of 516,700 shares, the days-to-cover ratio is currently 2.7 days. Approximately 3.4% of the shares of the stock are short sold. View Ingevity's Current Options Chain.

Some companies that are related to Ingevity include Johnson Matthey (JMPLY), Ashland Global (ASH), Huntsman (HUN), KURARAY CO LTD/ADR (KURRY), W. R. Grace & Co (GRA), SHOWA DENKO KK/ADR (SHWDY), Balchem (BCPC), Univar (UNVR), Chemours (CC), Innospec (IOSP), Olin (OLN), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM) and Hawkins (HWKN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include AbbVie (ABBV), Pfizer (PFE), Verizon Communications (VZ), Costco Wholesale (COST), Dominion Energy (D), General Electric (GE), Quaker Chemical (KWR), Boeing (BA), Alibaba Group (BABA) and Walt Disney (DIS).

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Ingevity's stock is owned by many different institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.05%), Fruth Investment Management (0.04%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Ingevity stock include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Katherine Pryor Burgeson, Michael P Smith, Phillip John Platt and Richard B Kelson. View institutional ownership trends for Ingevity.

NGVT stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Fruth Investment Management, and Louisiana State Employees Retirement System. Company insiders that have bought Ingevity stock in the last two years include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, and Richard B Kelson. View insider buying and selling activity for Ingevity.

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NGVT stock can currently be purchased for approximately $55.56.

Ingevity has a market capitalization of $2.29 billion and generates $1.29 billion in revenue each year. The company earns $183.70 million in net income (profit) each year or $4.93 on an earnings per share basis. Ingevity employs 1,850 workers across the globe.

The official website for Ingevity is www.ingevity.com.

Ingevity's mailing address is 5255 Virginia Avenue, North Charleston SC, 29406. The company can be reached via phone at 843-740-2300 or via email at [email protected]